+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Peptide Therapeutics Market 2019-2023 - Product Image

Global Peptide Therapeutics Market 2019-2023

  • ID: 4751578
  • Report
  • December 2018
  • Region: Global
  • 118 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • MORE
One of the major drivers of the global peptide therapeutics market is the growing cases of chronic diseases such as cancer, diabetes, obesity, and various cardiovascular diseases. Peptides are known to have high efficacy in the treatment of these diseases. Hence the use of peptides has increased significantly in recent years with the growing prevalence of chronic conditions. The high prevalence of chronic conditions leads to significant demand for curative drugs such as peptides thereby driving market growth. Moreover, the significant need for the treatment of these diseases has led various pharmaceutical companies to develop therapies, including peptide-based drugs. The analysts have predicted that the peptide therapeutics market will register a CAGR of almost 9% by 2023.

Market Overview

Novel drug delivery

Currently the treatment of various diseases with peptides is predominantly done by administering drugs through the parenteral route. The parenteral RoA is considered to be one of the most undesirable routes for patients due to the invasive nature of the drug administration. Hence, vendors are focusing on developing better drug delivery systems. The increasing need for novel drug delivery systems has led to the development of self-injectable pens by various vendors.

Stringent regulatory policies

One of the major challenges faced by the global peptide therapeutics market is the stringent policies set by regulatory bodies globally. The policies set for the approval of biologic drugs by regulatory bodies are more stringent than for small molecules, which makes it difficult for pharmaceutical companies to launch these drugs in the market. The late launch of drugs or FDA refusal of a drug can hinder the growth of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the peptide therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • 2.1 Preface
  • 2.2 Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY ROA
  • Market segmentation by RoA
  • Comparison by RoA
  • Parenteral - Market size and forecast 2018-2023
  • Oral - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by RoA
PART 07: MARKET SEGMENTATION BY INDICATION

PART 08: MARKET SEGMENTATION BY TECHNOLOGY

PART 09: CUSTOMER LANDSCAPE

PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: RoA - Market share 2018-2023 (%)
Exhibit 19: Comparison by RoA
Exhibit 20: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by RoA
Exhibit 27: Market share by 2018-2023 (%)
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Eli Lilly - Vendor overview
Exhibit 47: Eli Lilly - Business segments
Exhibit 48: Eli Lilly - Organizational developments
Exhibit 49: Eli Lilly - Geographic focus
Exhibit 50: Eli Lilly - Segment focus
Exhibit 51: Eli Lilly - Key offerings
Exhibit 52: Eli Lilly - Key customers
Exhibit 53: Novo Nordisk - Vendor overview
Exhibit 54: Novo Nordisk - Business segments
Exhibit 55: Novo Nordisk - Organizational developments
Exhibit 56: Novo Nordisk - Geographic focus
Exhibit 57: Novo Nordisk - Segment focus
Exhibit 58: Novo Nordisk - Key offerings
Exhibit 59: Novo Nordisk - Key customers
Exhibit 60: Sanofi - Vendor overview
Exhibit 61: Sanofi - Business segments
Exhibit 62: Sanofi - Organizational developments
Exhibit 63: Sanofi - Geographic focus
Exhibit 64: Sanofi - Segment focus
Exhibit 65: Sanofi - Key offerings
Exhibit 66: Sanofi - Key customers
Exhibit 67: Takeda Pharmaceutical - Vendor overview
Exhibit 68: Takeda Pharmaceutical - Business segments
Exhibit 69: Takeda Pharmaceutical - Organizational developments
Exhibit 70: Takeda Pharmaceutical - Geographic focus
Exhibit 71: Takeda Pharmaceutical - Key offerings
Exhibit 72: Takeda Pharmaceutical - Key customers
Exhibit 73: Teva Pharmaceutical - Vendor overview
Exhibit 74: Teva Pharmaceutical - Business segments
Exhibit 75: Teva Pharmaceutical - Organizational developments
Exhibit 76: Teva Pharmaceutical - Geographic focus
Exhibit 77: Teva Pharmaceutical - Segment focus
Exhibit 78: Teva Pharmaceutical - Key offerings
Exhibit 79: Teva Pharmaceutical - Key customers
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • MORE
Global Peptide Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global peptide therapeutics market: Eli Lilly, Novo Nordisk, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the recent advances in peptides therapeutics is expected to contribute significantly to market growth during our forecast period.”

According to the report, one of the major drivers for this market is the increasing strategic alliances are expected to contribute significantly to the growth of the market during our forecast period.

Further, the report states that one of the major factors hindering the growth of this market is the patent expiry of blockbuster drugs and the subsequently entry of biosimilar can restrict market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
Note: Product cover images may vary from those shown
Adroll
adroll